Results 171 to 180 of about 13,095,395 (361)
Molecular Oncology, EarlyView.Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata +10 more
wiley +1 more source
New frontiers for rare pulmonary diseases [PDF]
, 2005 This Issue of Sarcoidosis Vasculitis and Diffuse Lung Diseases is dedicated to a special event which was held in Milan in February 2005. The First International Conference on Rare Pulmonary Diseases and Orphan Drugs in Respiratory Medicine brought ...
Harari S., Agostini C.
core
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Signal Transduction and Targeted TherapyOligodendrocyte precursor cells (OPCs) rapidly respond to neural injury, becoming activated to preserve myelin homeostasis and interacting with diverse cell types in the central nervous system (CNS). However, the molecular basis of OPC communication with
Soonbong Baek +4 more
doaj +1 more source
Molecular Oncology, EarlyView.Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source
“Communication in rare diseases: A literature review for an empirical project” [PDF]
, 2014 According to the WHO a disease or disorder is defined as rare in Europe when it affects fewer than 1 in 2000. In the EU, as many as 30 million people alone may be affected by one of over 6000 rare diseases existing.
LIUCCIO, Michaela
core
Molecular Oncology, EarlyView.Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq +8 more
wiley +1 more source
Astrocyte heterogeneity in brain metastases
Molecular Oncology, EarlyView.Astrocytes emerge as pivotal regulators of metastatic colonization, survival, immune remodeling, and therapy response associated with an increasing heterogeneity that requires spatially and longitudinally resolved approaches to uncover regulatory programs and guide context‐specific therapies.
Carolina Hernández‐Oliver +2 more
wiley +1 more source
From tumor‐centric to ecosystem‐based hypotheses in brain tumor research and care
Molecular Oncology, EarlyView.Primary brain tumors, whether in adults or children, present a major challenge because of their dramatic prognosis and the ongoing lack of efficient therapeutic approaches. In recent years, a shift has occurred from tumor‐centric concepts to a more holistic view of these tumors as dynamic ecosystems.
Julie Gavard +8 more
wiley +1 more source
Reform and Development of Rare Diseases Drug Evaluation and Approval in China [PDF]
Rare diseases have a significant and profound impact on society, the economy, and the healthcare system. The path to developing drugs for rare diseases is particularly arduous. Due to the small number of patients and limited market demand, pharmaceutical
AI Xing +6 more
core +1 more source